Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
236,234,693
-
Number of holders
-
82
-
Total 13F shares, excl. options
-
57,164,176
-
Shares change
-
-23,577,858
-
Total reported value, excl. options
-
$20,180,226
-
Value change
-
-$11,164,741
-
Put/Call ratio
-
49%
-
Number of buys
-
36
-
Number of sells
-
-81
-
Price
-
$0.3530
Significant Holders of Akebia Therapeutics, Inc. - Common Stock (AKBA) as of Q2 2022
151 filings reported holding AKBA - Akebia Therapeutics, Inc. - Common Stock as of Q2 2022.
Akebia Therapeutics, Inc. - Common Stock (AKBA) has 82 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 57,164,176 shares
of 236,234,693 outstanding shares and own 24% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (16,259,104 shares), ACADIAN ASSET MANAGEMENT LLC (7,339,043 shares), MILLENNIUM MANAGEMENT LLC (5,354,175 shares), SATTER MANAGEMENT CO., L.P. (4,652,561 shares), BlackRock Inc. (4,338,245 shares), FEDERATED HERMES, INC. (1,989,467 shares), GEODE CAPITAL MANAGEMENT, LLC (1,617,393 shares), RENAISSANCE TECHNOLOGIES LLC (1,482,300 shares), HRT FINANCIAL LP (1,103,737 shares), and AQR CAPITAL MANAGEMENT LLC (862,168 shares).
This table shows the top 82 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.